StoneX Group’s PHAXIAM Therapeutics S.A.. American Depositary Shares PHXM Stock Holding History

StoneX Group’s Portfolio PHXM Stock Details PHXM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,730	Closed	-$13.3K	–	767
2023 Q2	$13.3K	Buy	+1,730	New	+$15.2K	﹤0.01%	571

Other funds holding PHXM

ADL

Asset Dedication LLC San Francisco, California $1.59B AUM 26.56% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

StoneX Group's PHXM Position: Q3 2023 in Review

StoneX Group sold out of PHAXIAM Therapeutics S.A.. American Depositary Shares (PHXM) in Q3 2023, closing a stake of 1,730 shares — an estimated $13.3K sold.

StoneX Group first reported a position in PHXM in Q2 2023 and held it in 1 quarter. The position peaked at $13.3K in Q2 2023. 3 funds tracked by Wall St. Rank hold PHXM as of Q3 2023.

StoneX Group reported no remaining PHAXIAM Therapeutics S.A.. American Depositary Shares position as of Q3 2023 after selling out during the quarter.
StoneX Group sold 1,730 PHAXIAM Therapeutics S.A.. American Depositary Shares shares in Q3 2023, an estimated $13.3K.
StoneX Group first reported a position in PHAXIAM Therapeutics S.A.. American Depositary Shares in Q2 2023 and held it in 1 quarter.
StoneX Group's PHAXIAM Therapeutics S.A.. American Depositary Shares position peaked at $13.3K in Q2 2023.
3 funds tracked by Wall St. Rank held PHAXIAM Therapeutics S.A.. American Depositary Shares as of Q3 2023.

Based on StoneX Group's 13F filing for Q3 2023, filed 15 Nov 2023.